Tilray's Sales Beat Is Marred by Street Concerns About Valuation
This article is for subscribers only.
Tilray Inc. shares climbed as much as 4.6 percent before turning negative as investors weighed a mixed quarter that saw a wider-than-expected loss and higher operating costs even as revenue beat estimates.
The company expects 2019 revenue to at least triple from last year’s $43 million. And during the earnings call, management boasted of its ability to meet growing U.S. demand for hemp-derived CBD, the non-intoxicating cousin of THC, via its recent Manitoba Harvest acquisition.